EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Neurofibromin 1 (NF1) Splicing Mutation c.61-2A>G: From Aberrant mRNA Processing to Therapeutic Implications In Silico

Asta Blazyte, Hojun Lee iD, Changhan Yoon, Sungwon Jeon, Jaesuk Lee, Delger Bayarsaikhan, Jungeun Kim, Sangsoo Park, Juok Cho, Sun Ah Baek, Gabin Byun, Bonghee Lee und 1 weitere

International Journal of Molecular Sciences · 2026

DOI: 10.3390/ijms27031177 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Asta Blazyte und 12 weiteren Autor:innen. Beteiligte Einrichtung: Korean Genomics Center (KOGIC), Ulsan National Institute of Science and Technology (UNIST), Ulsan 44919, Republic of Korea. Hauptthemen laut MEDLINE: Neurofibromin 1, Neurofibromatosis 1, RNA Splicing, Genetic Therapy. Die Arbeit nennt 84 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ulsan City Research Fund, Genome Editing Research Program, Alchemist Project of the Korea Evaluation Institute of Industrial Technology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The neurofibromin 1 (NF1) splice-site mutation c.61-2A>G (rs1131691100) is a rare, pathogenic, autosomal dominant variant that disrupts NF1 tumor-suppressor function, causing neurofibromatosis type 1 (NF1). Its pathogenic mechanism is poorly understood, and the potential for personalized therapeutic genome editing remains unknown due to the absence of a standard framework for investigating splicing disorders. Here, we performed a comprehensive multi-omics analysis of a de novo c.61-2A>G case from South Korea, integrating short- and long-read whole genome sequencing, whole transcriptome sequencing, and methylation profiling. We confirm that c.61-2A>G abolishes the canonical splice acceptor site, activating a cryptic splice acceptor 16 nucleotides downstream in exon 2. This splicing shift generates a 16-nucleotide deletion, causing a frameshift and premature stop codon that truncates the protein’s N-terminal region. Long-read sequencing further reveals that the mutation creates a novel CpG dinucleotide, which is methylated in the majority of reads. Finally, we assessed therapeutic correction strategies, revealing that CRISPR-Cas9 prime editing is the only viable approach for in vivo correction. This study provides the first comprehensive multi-omics characterization of the NF1 c.61-2A>G mutation and establishes a minimal framework for precision therapeutic development in silico in monogenic splicing disorders.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neurofibromin 1Neurofibromatosis 1RNA SplicingGenetic TherapyMutationGene EditingPrecision MedicineMultiomicsExonsFrameshift MutationCodon, NonsenseDNA MethylationDinucleoside PhosphatesRNA, MessengerCRISPR-Cas SystemsComputer SimulationHumansMaleFemaleYoung AdultAdultMiddle AgedAgedAged, 80 and over

Stichwörter der Autor:innen

NF1alternative splicingc.61-2A>Ggene editinggene expressionneurofibromatosisprotein isoformrs1131691100

Substanzen

NF1 protein, humanNeurofibromin 1Codon, NonsenseCpG dinucleotideDinucleoside PhosphatesRNA, Messenger

Autor:innen und Institutionen

  • Korean Genomics Center (KOGIC), Ulsan National Institute of Science and Technology (UNIST), Ulsan 44919, Republic of Korea.
  • Department of Biomedical Engineering, Ulsan National Institute of Science and Technology (UNIST), College of Information and Biotechnology, Ulsan 44919, Republic of Korea.
  • School of Medicine, Gachon University, Incheon 21565, Republic of Korea.
  • AgingLab, Ulsan 44919, Republic of Korea.
  • nSAGE, Incheon 21999, Republic of Korea.
  • Personal Genomics Institute (PGI), Genome Research Foundation (GRF), Osong 28160, Republic of Korea.

ORCID-Profile: Hojun Lee, Jong Bhak

Förderung

  • Ulsan City Research Fund
  • Genome Editing Research Program
  • Alchemist Project of the Korea Evaluation Institute of Industrial Technology
  • Korea Planning & Evaluation Institute of Industrial Technology with support from the Ministry of Trade, Industry and Energy
  • Korea Government
  • Korea Health Technology R&D Project through the Korea Health Industry Development Institute

Zitieren

APA

Blazyte, A., Lee, H., Yoon, C., Jeon, S., Lee, J., Bayarsaikhan, D., Kim, J., Park, S., Cho, J., Baek, S. A., Byun, G., Lee, B., & Bhak, J. (2026). Neurofibromin 1 (NF1) Splicing Mutation c.61-2A>G: From Aberrant mRNA Processing to Therapeutic Implications In Silico. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27031177

Vancouver

Blazyte A, Lee H, Yoon C, Jeon S, Lee J, Bayarsaikhan D, et al. Neurofibromin 1 (NF1) Splicing Mutation c.61-2A>G: From Aberrant mRNA Processing to Therapeutic Implications In Silico. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27031177

BibTeX
@article{Blazyte2026,
  author = {Blazyte, Asta and Lee, Hojun and Yoon, Changhan and Jeon, Sungwon and Lee, Jaesuk and Bayarsaikhan, Delger and Kim, Jungeun and Park, Sangsoo and Cho, Juok and Baek, Sun Ah and Byun, Gabin and Lee, Bonghee and Bhak, Jong},
  title = {Neurofibromin 1 (NF1) Splicing Mutation c.61-2A>G: From Aberrant mRNA Processing to Therapeutic Implications In Silico},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  doi = {10.3390/ijms27031177}
}
Kostenlos starten →